187 related articles for article (PubMed ID: 11056315)
1. Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast?
Karck U; Kommoss F
Eur J Cancer; 2000 Sep; 36 Suppl 4():S45-6. PubMed ID: 11056315
[TBL] [Abstract][Full Text] [Related]
2. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium.
Mourits MJ; Ten Hoor KA; van der Zee AG; Willemse PH; de Vries EG; Hollema H
J Clin Pathol; 2002 Jul; 55(7):514-9. PubMed ID: 12101196
[TBL] [Abstract][Full Text] [Related]
3. [Expression of hormonal receptors (alpha-estrogen, beta-estrogen, progesteron), Ki-67 and P53 in endometrium of tamoxifen treated breast cancer patients].
Negoiţă M; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):834-8. PubMed ID: 22046795
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
[TBL] [Abstract][Full Text] [Related]
5. Steroid receptor expression in endometria from women treated with tamoxifen.
Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
[TBL] [Abstract][Full Text] [Related]
6. Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen.
Elkas J; Armstrong A; Pohl J; Cuttitta F; Martínez A; Gray K
Obstet Gynecol; 2000 May; 95(5):697-703. PubMed ID: 10775732
[TBL] [Abstract][Full Text] [Related]
7. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and progesterone receptors of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen.
Cohen I; Shapira J; Beyth Y; Bernheim J; Tepper R; Cordoba M; Altaras MM
Gynecol Obstet Invest; 1998; 45(2):126-31. PubMed ID: 9517806
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen and progesterone receptor status in breast cancer and development of endometrial abnormalities.
Cohen I; Altaras M; Rosen DJ; Shapira Y; Cordoba M; Yigael D; Beyth Y
Lancet; 1992 Aug; 340(8814):312. PubMed ID: 1353229
[No Abstract] [Full Text] [Related]
11. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
[TBL] [Abstract][Full Text] [Related]
12. [Tamoxifen and endometrial pathology].
Negoiţă M; Terinte C; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1114-7. PubMed ID: 21500468
[TBL] [Abstract][Full Text] [Related]
13. [Morphologic endometrium changes with tamoxifen].
Dallenbach-Hellweg G; Hahn U; Schmidt D
Zentralbl Gynakol; 1996; 118(6):365-9. PubMed ID: 8768015
[TBL] [Abstract][Full Text] [Related]
14. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer.
Noguchi S; Motomura K; Inaji H; Imaoka S; Koyama H
Cancer; 1993 Jul; 72(1):131-6. PubMed ID: 8508397
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and progesterone receptor expression of decidual endometrium in a postmenopausal woman treated with tamoxifen and megestrol acetate.
Cohen I; Shulman A; Altaras M; Tepper R; Cordoba M; Beyth Y
Gynecol Obstet Invest; 1994; 38(2):127-9. PubMed ID: 7959340
[TBL] [Abstract][Full Text] [Related]
17. Variation of estrogen and progesterone receptor status in breast cancer after tamoxifen therapy.
Melchor JC; Rodríguez-Escudero FJ; Luján S; Corcóstegui B
Oncology; 1990; 47(6):467-70. PubMed ID: 2123023
[TBL] [Abstract][Full Text] [Related]
18. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.
Namer M; Lalanne C; Baulieu EE
Cancer Res; 1980 May; 40(5):1750-2. PubMed ID: 7371003
[TBL] [Abstract][Full Text] [Related]
19. Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms.
Neulen J; Williams RF; Breckwoldt M; Chwalisz K; Baulieu EE; Hodgen GD
Hum Reprod; 1996 Jul; 11(7):1533-7. PubMed ID: 8671500
[TBL] [Abstract][Full Text] [Related]
20. Megestrol acetate may stimulate the production of insulin-like growth factor 1 in breast tissues of women with breast cancer.
Fahlén M; Löfgren L; von Schoultz E; Naessén S; Carlström K; Söderqvist G
Horm Mol Biol Clin Investig; 2013 Jun; 13(3):51-4. PubMed ID: 25436713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
